A three-year investigation by Universiti Malaysia Kelantan has uncovered promising medical applications for a humble but underutilised creature—the local buffalo leech. Scientists have successfully isolated proteins from the saliva of Hirudinaria manillensis that demonstrate anticoagulant capabilities, potentially opening new avenues for treating blood-clotting disorders and supporting surgical procedures. This discovery, while grounded in traditional knowledge of leech therapy, marks an important step toward modernising natural remedies through rigorous scientific validation.
The research team, led by Dr Zulhisyam Abdul Kari from UMK's Faculty of Agro-Based Industry, identified hirudin as the active compound responsible for the anticoagulant effect. This protein functions in ways comparable to heparin, the synthetic anticoagulant widely administered in hospitals to prevent blood clots during and after surgery. Laboratory testing confirmed that protein extracts derived from buffalo leech saliva successfully delayed blood clotting in controlled conditions, matching the efficacy of established pharmaceutical alternatives. The finding gains significance given Malaysia's position as a source of high-quality leeches, a distinction that has attracted interest from developed nations seeking superior biological specimens.
Why buffalo leeches rather than their land-dwelling cousins? The distinction matters considerably for both yield and quality. Buffalo leeches produce substantially greater quantities of saliva and generate superior protein yields compared to land leeches, making them more economically viable for large-scale extraction and processing. This biological advantage positions Malaysian buffalo leeches as particularly valuable for commercial pharmaceutical development. Several neighbouring countries, recognising this value, have imported Malaysian leeches to supply their own medical markets, suggesting established international demand exists for further exploration of leech-derived therapeutics.
Leech therapy itself represents no modern invention. For centuries, traditional medicine practitioners across Asia have employed leeches to address diverse health conditions ranging from gout and acne to chronic wound management in diabetic patients. Modern medical facilities conducting leech therapy maintain stringent protocols to prevent cross-infection, using each leech exclusively for a single patient before appropriate disposal. Germany and other developed nations have become significant importers of Asian leeches specifically for pre-surgical applications, recognising that high-quality specimens enhance blood flow and improve surgical outcomes. This historical and contemporary medical endorsement validates the scientific investigation now underway in Malaysia.
Yet Malaysia's leech farming sector, once promising, has contracted dramatically in recent years. Expansion through contract farming arrangements that characterised earlier periods has given way to contraction and lost investor confidence. Dr Zulhisyam attributed this decline substantially to fraud issues that damaged trust among both local entrepreneurs and industry stakeholders. The reputational damage from these incidents created reluctance to invest in what might otherwise represent a profitable agricultural enterprise. This erosion of confidence occurred at a critical moment when structured farming could have positioned Malaysia as a global supplier of medically-grade leeches.
Natural leech populations face mounting pressure from multiple directions. Paddy fields and wetland habitats that historically harboured substantial leech populations have experienced dramatic species decline. The culprit, Dr Zulhisyam explained, lies partly in agricultural intensification—specifically the widespread deployment of uncontrolled pesticide and chemical fertiliser applications. These substances, essential to modern farming yields, inadvertently destroy the aquatic ecosystems upon which leeches depend. As farming practices have intensified across Southeast Asia, leech populations have contracted, reducing both wild-harvesting opportunities and natural breeding stock for farmed populations.
Regulatory authority over leeches shifted significantly in 2011 when responsibility transferred from the Department of Wildlife and National Parks (PERHILITAN) to the Department of Fisheries Malaysia. This administrative reorganisation reflected recognition that leeches warranted classification as an aquatic resource rather than wildlife. The change positioned leeches within a framework emphasising sustainable management and commercial potential. However, the regulatory transition alone cannot address the fundamental challenges of habitat degradation and industry confidence restoration without accompanying investment and policy support.
Accelerating commercialisation of leech-derived pharmaceuticals demands substantially increased research funding. Dr Zulhisyam emphasised that molecular biology investigations must expand to characterise the complete spectrum of bioactive compounds present in buffalo leech saliva. Understanding the biochemical mechanisms underlying hirudin's anticoagulant properties could unlock applications beyond simple blood clotting prevention. Comprehensive research into protein purification, stability, and pharmaceutical formulation requires resources currently unavailable through conventional academic channels. International pharmaceutical companies have demonstrated interest in natural-source anticoagulants, suggesting commercial viability exists if Malaysian research can deliver sufficiently rigorous scientific documentation.
The leech conservation agenda extends beyond simple species preservation. Dr Zulhisyam articulated a broader perspective positioning leeches as valuable natural resources embedded within functioning ecosystems. Every organism contributes to ecological balance through mechanisms often poorly understood. Leeches play roles in nutrient cycling, food web dynamics, and ecosystem health that remain incompletely characterised. Destroying leech populations through environmental degradation potentially creates cascading ecological consequences extending far beyond the loss of a single commercial resource. This systems-thinking approach resonates particularly strongly in Malaysia, where biodiversity comprises enormous unrealised pharmaceutical and biotechnological potential.
For Malaysian policymakers and investors, this research presents an intriguing proposition. Restoring and expanding leech farming, coupled with investment in pharmaceutical research and development, could create employment opportunities while generating export revenue from value-added biological products. Neighbouring countries' demonstrated willingness to import Malaysian leeches suggests competitive advantage exists. However, rebuilding industry confidence after fraud-related damage requires transparent governance, quality certification standards, and perhaps government incentive schemes. Thailand's successful leech importation demonstrates that Southeast Asian markets recognise value in premium-quality specimens.
The broader narrative here concerns how emerging economies can leverage indigenous biological resources through scientific validation and modern commercialisation. Malaysia possesses recognised leech populations, established harvesting knowledge, and growing research capacity. The missing elements involve coordinated investment, regulatory clarity, and trust restoration. Unlike extracted minerals or harvested timber, sustainable leech farming regenerates naturally when environmental conditions support breeding populations. This renewable characteristic positions leech farming favourably within sustainability frameworks increasingly influencing international trade and investment decisions. For Malaysia, revitalising this sector could demonstrate how traditional ecological knowledge merges with contemporary science to generate competitive advantage in global biotechnology markets.
Looking forward, successful commercialisation requires multiple stakeholders aligning around shared objectives. Researchers need funding to advance pharmaceutical applications. Farmers need market guarantees and technical support to invest in leech farming. Regulators need authority and resources to manage sustainability. The general public requires education about leeches as valuable resources rather than pests. When these elements align, as they have in other countries' biotechnology sectors, what once seemed marginal becomes mainstream. Malaysia's buffalo leech represents one such opportunity—scientifically validated, commercially promising, and ecologically sound if properly managed. Whether the nation seizes this potential depends on coordinated commitment from government, industry, and academia during this critical window when international interest and domestic research capacity coincide.
